Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.10
Preservative: 0.1% Proclin
Constituents: 0.2% BSA, PBS
Concentration information loading...
PurityImmunogen affinity purified
- Epigenetics and Nuclear Signaling
- Domain Families
- HLH / Leucine Zipper
- HLH / Leucine Zipper
- Human c-Myc peptide (ab166837)
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
- 450 nm Stop Solution for TMB Substrate (ab171529)
- 650 nm Stop Solution for TMB Substrate (ab171531)
- Immunoassay Blocking Buffer (ab171534)
- Immunoassay Blocking (BSA Free) (ab171535)
Our Abpromise guarantee covers the use of ab19312 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 µg/ml.|
|ELISA||1/10000 - 1/100000.|
|WB||1/1000 - 1/10000. Predicted molecular weight: 49 kDa. Colorimetric. Chemiluminescent: 1/1000 - 1/30000.|
FunctionParticipates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.
Involvement in diseaseNote=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors.
Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.
Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
Sequence similaritiesContains 1 basic helix-loop-helix (bHLH) domain.
modificationsPhosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.
Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.
Cellular localizationNucleus > nucleoplasm. Nucleus > nucleolus.
- Information by UniProt
Formc-Myc is also expressed in the cytoplasm.
- AU016757 antibody
- Avian myelocytomatosis viral oncogene homolog antibody
- bHLHe39 antibody
ICC/IF image of ab19312 stained human HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1% BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab19312, 1 µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue).
All lanes : Anti-c-Myc antibody (HRP) (ab19312) at 0.4 µg/ml
Lane 1 : E. coli whole cell lysate expressing a multi-tag fusion protein at 0.2 µg
Lane 2 : E. coli whole cell lysate expressing a multi-tag fusion protein at 0.1 µg
Lane 3 : E. coli whole cell lysate expressing a multi-tag fusion protein at 0.05 µg
Predicted band size: 49 kDa
Exposure time: 10 seconds
This product has been referenced in:
- Wang Q et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis 9:739 (2018). Read more (PubMed: 29970892) »
- Hayden RS et al. Cell-tethered ligands modulate bone remodeling by osteoblasts and osteoclasts. Adv Funct Mater 24:472-479 (2014). Read more (PubMed: 25419210) »